Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 97Neoplasms 28Carcinoma, Non-Small-Cell Lung 27Neoplasm Metastasis 23Urinary Bladder Neoplasms 17Colorectal Neoplasms 17Sarcoma 15Lung Neoplasms 14Biliary Tract Neoplasms 13Ovarian Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Breast Neoplasms 12Lymphoma 10Cholangiocarcinoma 10Recurrence 9Hodgkin Disease 8Carcinoma, Transitional Cell 8Adenocarcinoma 8Lymphoma, Non-Hodgkin 7Triple Negative Breast Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 6Lymphoma, Follicular 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5Rectal Neoplasms 5Gastrointestinal Neoplasms 5Colonic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Multiple Myeloma 4Lymphoma, T-Cell, Peripheral 4

Interventions

Imatinib Mesylate 4ripretinib 2pexidartinib 2binimetinib 2Sunitinib 2tinostamustine 1spartalizumab 1pembrolizumab 1avapritinib 1Radiotherapy 1Injections 1HhAntag691 1Gemcitabine 1Everolimus 1Drug Therapy 1Blood Specimen Collection 1Biopsy 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Gastrointestinal Stromal Tumors × Gemcitabine × Clear all
NCT02632448 2025-05-02

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Esperas Pharma Inc.

Phase 1/2 Completed
229 enrolled
BreastGastrointestinalGynecologicSarcoma

Breast Neoplasms, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡